Mounjaro sales jump 502% to ₹1,256 crore as GLP-1 demand accelerates in India
Mounjaro has become India’s top-selling pharma brand, posting ₹1,256 crore in moving annual total sales through August 2026. Its 502% rise far outpaced the 10.4% growth of the overall pharma market and 15.2% growth in antidiabetics, signalling rapid consumer uptake of GLP-1 therapies.
What happened
Mounjaro became India’s top-selling pharma brand, with MAT sales of ₹1,256 crore, up 502%, as GLP-1 diabetes and weight-management therapies outpaced the
Key facts
- India pharma market growth: 10.4%
- Antidiabetic segment value growth: 15.2%
- Mounjaro MAT sales: ₹1,256 crore
- Mounjaro sales growth: 502%
Why this matters
India’s accelerating GLP-1 adoption increases the strategic value of obesity-care platforms, local manufacturing partners and metabolic-disease portfolios.
What to watch
- Monthly Mounjaro prescription growth versus repeat-fill rates, which will distinguish trial demand from durable therapy adoption.
- New GLP-1 approvals, launch timelines and pricing from Novo Nordisk, Indian pharmaceutical companies and biosimilar/generic entrants.
- Evidence of supply shortages, pharmacy stock-outs, cold-chain failures or counterfeit-product enforcement actions.
- Expansion of obesity-treatment reimbursement by insurers, employers, corporate hospitals or public health schemes.
- Changes in sales of protein nutrition, diabetes diagnostics, bariatric services and fitness memberships in major Indian metros.
- Regulatory guidance on online sale, advertising, off-label obesity prescribing and safety monitoring for GLP-1 therapies.
- Large pharmacy chains and e-pharmacies will build GLP-1 discovery, prescription-routing, refill-reminder and cold-chain delivery journeys.
- Hospitals, diabetologists and obesity clinics will package GLP-1 prescriptions with diagnostics, dietitian access, body-composition monitoring and follow-up subscriptions.
- Consumer brands will target GLP-1 users with high-protein, portion-controlled, gut-health and micronutrient-positioned products, while restaurants test lighter and protein-forward menus.
- Insurers and employers will evaluate selective obesity and metabolic-care coverage, initially tied to diabetes risk, BMI thresholds and clinical monitoring.
- Eli Lilly and rivals will expand physician education, supply capacity and patient-support programs to improve persistence and defend share.